Irinotecan News and Research RSS Feed - Irinotecan News and Research

Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
Study identifies genetic alterations that contribute to growth and recurrence of Ewing sarcoma

Study identifies genetic alterations that contribute to growth and recurrence of Ewing sarcoma

An international collaboration has identified frequent mutations in two genes that often occur together in Ewing sarcoma (EWS) and that define a subtype of the cancer associated with reduced survival. [More]
Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival. [More]
Irinotecan-based therapy improves survival rates for patients with stage III colon cancer

Irinotecan-based therapy improves survival rates for patients with stage III colon cancer

A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. [More]
Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. [More]
Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the past 12 months. [More]
Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected. [More]
Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years. [More]
Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
New drug shows promising results in patients with advanced pancreatic cancer

New drug shows promising results in patients with advanced pancreatic cancer

A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute, showed that a new drug called MM-398, given in combination with 5-flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously-treated pancreatic cancer. [More]
Patients with advanced colorectal cancer respond well to new combination therapy

Patients with advanced colorectal cancer respond well to new combination therapy

In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. [More]
Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC). [More]
Amrubicin promise for etoposide-naïve SCLC patients

Amrubicin promise for etoposide-naïve SCLC patients

Patients with chemotherapy-refractory small-cell lung cancer may benefit from treatment with the topoisomerase II inhibitor amrubicin, research from Japan suggests. [More]

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Kinex Pharmaceuticals, Inc. announced today that the United States Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for Oratecan, an oral form of an approved anti-cancer drug irinotecan with enhanced oral absorption. [More]

Amrubicin regimen inferior to irinotecan for extensive SCLC

Irinotecan plus cisplatin remains the gold standard for Japanese patients with extensive small-cell lung cancer, say researchers, after amrubicin plus cisplatin failed to improve survival in their randomised phase III trial. [More]
Tgen professor to receive 2014 Hope Funds Award for developing numerous cancer treatments

Tgen professor to receive 2014 Hope Funds Award for developing numerous cancer treatments

Dr. Daniel D. Von Hoff, who has been instrumental in developing numerous new cancer treatments, is among this year's recipients of the Award of Excellence from the Hope Funds for Cancer Research. [More]
Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

In association with its 50th anniversary, the American Society of Clinical Oncology has named Dr. Daniel D. Von Hoff one of ASCO's 50 Oncology Luminaries, celebrating 50 doctors who over the past half-century have significantly advanced cancer care. [More]